Prevalence and incidence of HCV infection among Vietnam heroin users with recent onset of injection

Journal of Urban Health

Volumn 87, Issue 2, 2010, Pages 278-291

  Clatts, Michael C ^a   Colón López, Vivian ^a   Giang, Le M ^b   Goldsamt, Lloyd A ^c  

^a UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^b HANOI MEDICAL UNIVERSITY   (Viet Nam)

^c NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

Author keywords

Harm reduction; HCV incidence; Hepatitis C prevalence; IDU's; Onset and initiation of heroin injection; Vietnam

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; EPIDEMIOLOGY; HARM REDUCTION; HEPATITIS C; HEROIN DEPENDENCE; HUMAN; MALE; PROSPECTIVE STUDY; SUBSTANCE ABUSE; VIET NAM;

ADOLESCENT; ADULT; HARM REDUCTION; HEPATITIS C, CHRONIC; HEROIN DEPENDENCE; HUMANS; MALE; PROSPECTIVE STUDIES; SEROEPIDEMIOLOGIC STUDIES; SUBSTANCE ABUSE, INTRAVENOUS; VIETNAM; YOUNG ADULT;

EID: 77953664660     PISSN: 10993460     EISSN: 14682869     Source Type: Journal    
DOI: 10.1007/s11524-009-9417-9     Document Type: Article

References (30)

1. Day C, Dolan K. Correlates of hepatitis C testing among heroin injectors in Sydney. Health Promot J Austr. 2006; 17(1): 70-72.
2. Garfield J, Drucker E. Fatal overdose trends in major US cities: 1990-1997. Addictions Research and Theory. 2001; 9(5): 425-436.
3. Wood E, Kerr T, Stoltz J, et al. Prevalence and correlates of hepatitis C infection among users of North America's first medically supervised safer injection facility. Public Health. 2005; 119(12): 1111-1115.
4. Sulkowski M. Viral hepatitis and HIV coinfection. J Hepatol. 2008; 48(2): 353-367.
5. Doherty MC, Garfein RS, Monterroso E, Brown D, Vlahov D. Correlates of HIV infection among young adult short-term injection drug users. AIDS. 2000; 14(6): 717-726. (Pubitemid 30229351)
6. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health. 1996; 86(5): 655-661.
7. Hagan H, Thiede H, Des Jarlais DC. Hepatitis C virus infection among injection drug users: survival analysis of time to seroconversion. Epidemiology. 2004; 15(5): 543-549.
8. Hagan H, Des Jarlais DC, Stern R, et al. HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection. Int J Drug Policy. 2007; 18 (5): 341-351.
9. Roy E, Haley N, Leclerc P, Cedras L, Boivin JF. Drug injection among street youth: the first time. Addiction. 2002; 97(8): 1003-1009.
10. van Ameijden EJ, van den Hoek JA, Hartgers C, Coutinho RA. Risk factors for the transition from noninjection to injection drug use and accompanying AIDS risk behavior in a cohort of drug users. Am J Epidemiol. 1994; 139(12): 1153-1163.
11. Clatts MC, Goldsamt LA, Yi H. Drug and sexual risk in four men who have sex with men populations: evidence for a sustained HIV epidemic in New York City. J Urban Health. 2005; 82(1 Suppl 1): i9-i17.
12. Allison PD. Logistic Regression Using the SAS System: theory and Application. Cary, NC;1999.
13. Szklo M, Nieto FJ. Epidemiology: beyond the Basics. 2nd ed. Gaithersburg, Maryland; 2004.
14. Clatts MC, Giang LM, Goldsamt LA, Yi H. Novel heroin injection practices: implications for transmission of HIV and other bloodborne pathogens. Am J Prev Med. 2007; 32(6 Suppl): S226-S233.
15. Hahn JA, Page-Shaffer K, Lum PJ, Ochoa K, Moss AR. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology. 2001; 34(1): 180-187.
16. Miller CL, Johnston C, Spittal PM, et al. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology. 2002; 36 (3): 737-742.
17. Thorpe LE, Ouellet LJ, Levy JR, Williams IT, Monterroso ER. Hepatitis C virus infection: prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997-1999. J Infect Dis. 2000; 182(6): 1588-1594.
18. Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol. 1998; 18(Suppl 1): S11-S19.
19. Amin J, Kaye M, Skidmore S, Pillay D, Cooper DA, Dore GJ. HIV and hepatitis C coinfection within the CAESAR study. HIV Med. 2004; 5(3): 174-179.
20. Klein MB, Lalonde RG, Suissa S. The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2003; 33(3): 365-372.
21. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 2000; 356(9244): 1800-1805.
22. Fainboim H, Gonzalez J, Fassio E, et al. Prevalence of hepatitis viruses in an anti-human immunodeficiency virus-positive population from Argentina. A multicentre study. J Viral Hepat. 1999; 6(1): 53-57.
23. Solomon SS, Srikrishnan AK, Mehta SH, et al. High prevalence of HIV, HIV/hepatitis C virus coinfection, and risk behaviors among injection drug users in Chennai, India: a cause for concern. J Acquir Immune Defic Syndr. 2008; 49(3): 327-332.
24. Reyes JC, Robles RR, Colon HM, et al. HIV and HCV co-infection among street-recruited injection drug users in San Juan, Puerto Rico. Int ConfAIDS. 2004 Jul 11-16; 15: abstract no. C12400. http://gateway.nlm.nih.gov/ MeetingAbstracts/ma?f=1022775 77.html. Accessed December 3, 2008.
25. Maher L, Jalaludin B, Chant KG, et al. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction. 2006; 101(10): 1499-1508.
26. Roy E, Boudreau JF, Boivin JF. Hepatitis C virus incidence among young street-involved IDUs in relation to injection experience. Drug Alcohol Depend. 2009; 102(1-3): 158-161.
27. Kapadia F, Latka MH, Hagan H, et al. Design and feasibility of a randomized behavioral intervention to reduce distributive injection risk and improve health-care access among hepatitis C virus positive injection drug users: the Study to Reduce Intravenous Exposures (STRIVE). J Urban Health. 2007; 84(1): 99-115.
28. Clatts MC, Heimer R, Abdala N, et al. HIV-1 transmission in injection paraphernalia: heating drug solutions may inactivate HIV-1. JAcquir Immune Defic Syndr. 1999; 22(2): 194-199.
29. Vinh D. A qualitative study on HIV risk among injecting drug users in Vietnam: reasons for sharing syringes and needles. 2002. Int Conf AIDS. 2002 Jul 7-12; 14: abstract no. WeOrE1361.http://gateway.nlm.nih.gov/MeetingAbstracts/ ma?f=102251200.html. Accessed December 11, 2008.
30. Doussantousse S, Hoa NT. The life and times of the Hanoi drug users: some recent insights from field research. A research report to the UNDCP, UNAIDS, Vietnam. 2001. http://www.ahrn.net/library-upload/uploadfile/HanoiDrug.pdf. Accessed November 13, 2008.